IGM Biosciences Q4 2022 Earnings Report $1.15 -0.09 (-7.26%) As of 04:00 PM Eastern Earnings HistoryForecast IGM Biosciences EPS ResultsActual EPS-$1.19Consensus EPS -$1.53Beat/MissBeat by +$0.34One Year Ago EPS-$1.50IGM Biosciences Revenue ResultsActual Revenue$0.37 millionExpected Revenue$15.27 millionBeat/MissMissed by -$14.90 millionYoY Revenue GrowthN/AIGM Biosciences Announcement DetailsQuarterQ4 2022Date3/30/2023TimeQ4 2022 Earnings ReleaseConference Call ResourcesConference CallConference Call TranscriptPress ReleaseIGMS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads IGM Biosciences Earnings HeadlinesIGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Recommendation of "Reduce" by AnalystsMarch 30 at 2:53 AM | americanbankingnews.comIGM Biosciences (IGMS) Gets a Hold from RBC CapitalMarch 7, 2025 | markets.businessinsider.comThis trading frustration almost made me quitThis happened to me time and time again, and I wanted no more of it. That’s exactly why I set out to refine my strategy… And with the help of my good friend Nate, we have done exactly that… Now, I cannot promise future returns or against losses, but the real trades so far have been nothing but astounding. Turning my once 69% win rate, into 83.3% on real trades in the last two months. And instead of just telling you, I want to SHOW you. March 31, 2025 | WealthPress (Ad)Morgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)March 7, 2025 | markets.businessinsider.comIgm BiosciencesFebruary 16, 2025 | forbes.comIGM Biosciences (IGMS) Receives a Hold from Bank of America SecuritiesFebruary 13, 2025 | markets.businessinsider.comSee More IGM Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IGM Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGM Biosciences and other key companies, straight to your email. Email Address About IGM BiosciencesIGM Biosciences (NASDAQ:IGMS), a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.View IGM Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
